Stop signal for Ataluren as PTC regains nonsense asset from Genzyme
This article was originally published in Scrip
Executive Summary
PTC Therapeutics has regained worldwide rights to its troublesome Phase III rare disease candidate ataluren (PTC 124) from Genzyme (Sanofi).